Cortendo names new chair
This article was originally published in Scrip
Cortendo, a global biopharmaceutical company focused on orphan endocrine disorders, has appointed John H Johnson chair of its board of directors and named Richard Kollender a director. These appointments, proposed by the nomination committee, were approved by shareholders during the Extraordinary General Meeting on 17 March. Mr Johnson has more than 30 years of biopharmaceutical industry experience at organizations including Johnson & Johnson, Lilly, ImClone and Pfizer. He is currently a member of the board of directors of Cempra Pharmaceuticals, Histogenics, Portola Pharmaceuticals, and Sucampo Pharmaceuticals. He previously served as chair of Dendreon and Tranzyme Pharma, and also served as a member of the board of directors of Pharmaceutical Research and Manufacturers of America (PhRMA), the Health Section Governing Board of Biotechnology Industry Organizations (BIO), and BioNJ.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.